Condition category
Infections and Infestations
Date applied
Date assigned
Last edited
Retrospectively registered
Overall trial status
Recruitment status

Plain English Summary

Background and study aims
Infectious disease is the single biggest cause of death worldwide. New infectious agents require investigation to understand its characteristics and how infection with this pathogen results in a disease process. We need to understand risk factors for severe illness and how to best treat disease caused by this pathogen. In order to develop a mechanistic understanding of disease processes, such that risk factors for severe illness can be identified and treatments can be developed, it is necessary to understand pathogen characteristics associated with virulence, the replication dynamics and in-host evolution of the pathogen, the dynamics of the host response, the pharmacology of antimicrobial or host-directed therapies, the transmission dynamics, and factors underlying individual susceptibility.
This study is designed for the rapid, coordinated clinical investigation of patients with confirmed infection with a pathogen of public interest. The study has been designed to maximize the likelihood that as much data as possible is collected and shared rapidly in a format that can be easily aggregated, tabulated and analysed across many different settings globally. The study is designed to have some level of flexibility in order to ensure the broadest acceptance.

Who can participate?
Any patient of any age who is admitted to a participating acute hospital with confirmed infection with a pathogen of public interest.

What does the study involve?
The study can be delivered at different Tiers according to local resources at participating sites.
In all instances, data regarding clinical presentation (symptoms and clinical signs), treatments in hospital, past medical history/background for all patients in the study are collected throughout their hospital admission.
For sites operating at Tier 0: there is the above data collection only.
For sites operating at Tier 1: there is the above data collection and samples are taken from patients on the first day in the study (blood samples, throat swab, collecting fluid from the nose and mouth (using safe, specialised equipment), urine, faeces).
For sites operating at Tier 2: the above data collection, and samples as mentioned above on the first day in the study and at subsequent time points in the first two weeks of their hospital admission. Four weeks after discharge, patients are invited back to have repeat samples taken.

What are the possible benefits and risks of participating?
Benefits: There will be no direct benefit to research participants. The study may include biological sampling in addition to sampling required for medical management. The results of the tests done on these samples may not contribute to improving the participant's health. The results of this study will not be available in time to contribute to the participant's care. Where possible, test results with potential relevance to patient care will be informed to the participant and/or treating doctor. The feasibility of this will depend on local resources. Some assays cannot immediately benefit the patient because data will need to be pooled with others, or because the assays take time.
Risks: Inconvenience. Participation in this research study poses a minimal risk of inconvenience through household visits and attendance of follow-up visits. Appropriate compensation for travel costs to attend follow-up visits and for time of attending visits will be given according to the standard policies of the sponsor.
Phlebotomy. Participants may have blood drawn more often than is required for standard care. Phlebotomy can be associated with pain at the draw site and rarely with infection. Daily blood draw volumes have been restricted according to weight so that combined clinical and research sampling is within recommended limits. Discomfort will be minimized by having expert staff obtain blood samples, and by combining research sampling with routine clinical sampling, where possible, which normally occurs daily in acutely unwell patients in hospital.
Discomfort of throat swabs. Collecting throat swabs may be cause transient discomfort. Discomfort and risk will be minimized by using experienced clinical staff at each site, and samples will be taken at the same time as clinical samples in order to minimize these risks.
Discomfort of SAM strips. Collecting nasal fluid using SAM strips may be cause a transient tickling sensation during application and removal which can cause eye watering through a local reflex.
Oral (Crevicular) Fluid Collection. Oral crevicular fluid collection involves the participant or carer gently brushing a small sponge on a flexible plastic rod at the margin of the gums and teeth in exactly the same manner as is done for routine mouth care or teeth brushing. Apart from inconvenience and sensation, there is no expectation of and discomfort.
Incidental findings in genetic testing. This study includes genetic testing to identify host genetic variants associated with disease progression or severity. There is a very small chance that these tests may result in the incidental discovery of information that is relevant to the participant's health. Since the samples will be analysed anonymously in batches, and generally in non-clinical laboratories with investigational techniques, we will not attempt to identify and inform participants of any results from genetic tests. If we were to do so, there would be a considerable risk of accidental harm in the form of unnecessary anxiety and distress.
at risk venepuncture will be minimised by limiting research venepuncture to coincide with clinical venepuncture.

Where is the study run from?
The study is run from participating acute hospital sites in England, Wales and Scotland.

When is the study starting and how long is it expected to run for?
February 2020 to February 2023.

Who is funding the study?
1. Wellcome Trust (UK)
2. Medical Research Council (UK)
3. SPRINT-SARI NIHR Health Protection Research Unit (HPRU) in Respiratory Infection (UK)
4. HPRU in Emerging and Zoonotic Infections (UK)

Who is the main contact?
Unfortunately, this study is not recruiting public volunteers at this time. This is because the research isn’t ready for volunteers yet or the researchers are directly identifying volunteers in certain areas or hospitals. Please do not contact the research team as they will not be able to respond. For more information about COVID-19 research, visit the Be Part of Research homepage.

Trial website

Contact information



Primary contact

Prof Calum Semple


Contact details

Institute of Child Health
Alder Hey Children's Hospital
L12 2AP
United Kingdom
+44 (0)1512525250



Additional contact

Ms Hayley Hardwick


Contact details

CCP UK Programme Manager
HPRU EZI Clinical Research Manger
ZikaVac and FlaviPrime Project Manager
Institute of Infection and Global Health
University of Liverpool
Ronald Ross Building
8 West Derby Street
L69 7BE
United Kingdom
+44 (0)151 795 9672

Additional identifiers

EudraCT number

Nil known number

Nil known

Protocol/serial number

IRAS 126600, CPMS 14152

Study information

Scientific title

ISARIC WHO Clinical Characterisation Protocol for severe emerging infections UK: ISARIC WHO CCP-UK



Study hypothesis

The rapid, coordinated clinical investigation of severe or potentially severe acute infections by pathogens of public health interest

Ethics approval

Approved 24/02/2020, Oxford C Research Ethics Committee (Formally Oxford South Central C) (Level 3, Block B, Whitefriars, Lewins Mead, Bristol, BS1 2NT, UK; +44 (0)207 104 8041;, ref: 13/SC/0149

Study design

Observational cohort study

Primary study design


Secondary study design

Cohort study

Trial setting


Trial type


Patient information sheet


Emerging infections


Patients with confirmed infection with pathogen of public interest, or an appropriate consultee, will be approached by staff who will explain the details of the study to the patient or consultee and allow them time to discuss and ask questions. Patients who agree to be in the study will sign an informed consent form.

Patients will have a daily clinical review as per standard care and the following samples will be obtained:
1. Pathogen samples
- residual volumes of routine clinical samples will be stored
- the following samples will be obtained daily for the first week, every two days for the second week and weekly until resolution of acute disease to a maximum of 100 days:
Respiratory tract samples - samples from the throat (nasopharyngeal aspirates) or if the patient is on a ventilator, a sample from the windpipe (ET aspirate)
Swabs from infected sites (eg. skin lesions)

Pathogen samples will be examined by growing the infectious agent in a laboratory, and by reading its genetic code to understand how it changes over time and develops new characteristics. This will also tell us how the pathogen may be spread and how long people are infectious for.

2. Blood samples
A blood sample will be taken at recruitment, day 3, 9 and 28 days after recovery. The volume of blood depends on the weight of the patient as per the study protocol.

Samples will be tested for a range of measures of immune function, including antibody production and immune signalling molecules. This will enable us to better understand the immune response to infection.

Intervention type



Drug names

Primary outcome measure

At baseline, day three, day nine and > 28 days after hospital discharge:
1. Changes in pathogen during infection and during spread between individuals and development of resistance measured using:
1.1. Respiratory samples:
1.1.1. Nasal SAM strip
1.1.2. Throat swab in virus transport medium
1.1.3. Endotracheal aspirate if intubated,
1.1.4. Where resources permit, in infants/children who cannot take SAM strip, nasopharyngeal aspirate OR flocked nose swab in virus transport medium
1.2. Urine (up to 10ml)
1.3. Stool (up to 10ml) or rectal swab
1.4. Samples from infected sites/sores
1.5. Any residual from samples taken for clinical care
2. Non-invasive determination of humoral immune response measured using oral fluid (Crevicular fluid)
3. Mediators/biomarkers and serology measured using blood sample in serum (clotted) tube
4. Mediators/ metabolites/ biomarkers and RNA/DNA from pathogens measured using blood sample in EDTA tube
5. Microarray/RNA sequencing pathogen & host transcriptome measured using blood sample in blood RNA tube TempusTM (or PAXgene®)
6. For CNS infections only: additional cerebrospinal fluid sample during clinical lumbar puncture to measure Mediators/ metabolites/ biomarkers and RNA/DNA from pathogens and to perform serological testing for pathogen-specific antibodies

Secondary outcome measures


Overall trial start date


Overall trial end date


Reason abandoned (if study stopped)


Participant inclusion criteria

1. Patients (children and adults) with confirmed infection with a pathogen relevant to the study objectives
2. Inclusion criteria for SARI patients:
2.1. Acute respiratory illness patients of all ages with a history of fever or measured fever of >38°C and at least one respiratory symptom
2.2. High suspicion or confirmed infection with a respiratory pathogen relevant to the objectives of this protocol
2.3. Admitted to a healthcare facility
3. Inclusion criteria for VHF patients:
3.1. Sudden onset high fever and known contact with a person with suspected or confirmed VHF
3.2. Sudden onset of fever with at least three of the following symptoms: headache; anorexia; lethargy; aching muscles or joints; breathing difficulties; vomiting; diarrhoea; stomach pain; dysphagia; hiccups
3.3. High suspicion or confirmed infection with a VHF pathogen relevant to the objectives of this protocol
3.4. Admitted to a healthcare facility
4. Inclusion criteria for patients with CNS infection
4.1. Fever >=38C or history of fever within 30 days in patients of all ages with one of:
4.1.1. Altered consciousness (including reduced conscious level, confusion, or a change in personality or behaviour)
4.1.2. New onset of seizures (excluding simple febrile seizures)
4.1.3. New onset focal neurological deficit
4.2. Electroencephalographic (EEG), neuroimaging or cerebrospinal fluid examination findings indicative of central nervous system infection
4.3. High likelihood of infection with a neuroinvasive pathogen of public health interest
4.4. Admitted to a healthcare facility
4.5. Confirmed infection with a neuroinvasive pathogen of public health interest and admitted to a healthcare facility
5. Inclusion criteria for patients with infection by pathogens of public health interest:
This study will enrol eligible patients with suspected or confirmed infection with a pathogen of public health interest. These pathogens will be listed by the investigators taking into consideration position statements issued by World Health Organisation, Public Health England and other authorities.

Participant type


Age group




Target number of participants

Planned Sample Size: 100; UK Sample Size: 100

Participant exclusion criteria

Refusal to participate

Recruitment start date


Recruitment end date



Countries of recruitment

United Kingdom

Trial participating centre

Wythenshawe Hospital
Manchester University NHS Foundation Trust Southmoore Road Wythenshawe
M23 9QT
United Kingdom

Trial participating centre

Acute NHS trusts and Community Hospital NHS Trusts and Mental Health NHS Trusts in the United Kingdom are open to recruitment
United Kingdom

Sponsor information


University of Oxford

Sponsor details

Clinical Trials and Research Governance
Boundary Brook House
United Kingdom
+44 (0)1865 616480

Sponsor type




Funder type

Research organisation

Funder name

Wellcome Trust

Alternative name(s)

Funding Body Type

private sector organisation

Funding Body Subtype

International organizations


United Kingdom

Funder name

Medical Research Council

Alternative name(s)


Funding Body Type

government organisation

Funding Body Subtype

National government


United Kingdom

Funder name

SPRINT-SARI NIHR Health Protection Research Unit (HPRU) in Respiratory Infection

Alternative name(s)

Funding Body Type

Funding Body Subtype


Funder name

HPRU in Emerging and Zoonotic Infections

Alternative name(s)

Funding Body Type

Funding Body Subtype


Results and Publications

Publication and dissemination plan

Planned publication in a high-impact peer-reviewed journal.

IPD sharing statement:
The current data sharing plans for this study are unknown and will be available at a later date.

Intention to publish date


Participant level data

To be made available at a later date

Basic results (scientific)

Publication list

2020 protocol and results in (added 28/05/2020)
2020 results for children and young people in (added 28/08/2020)
2020 results in (added 11/09/2020)

Publication citations

Additional files

Editorial Notes

23/09/2020: Added PubMed address. 11/09/2020: Publication reference added. 28/08/2020: Publication reference added. 28/05/2020: Publication reference added. 22/05/2020: The following changes have been made: 1. The scientific title has been changed from "ISARIC/WHO Clinical characterisation protocol for severe emerging infections" to "ISARIC WHO Clinical Characterisation Protocol for severe emerging infections UK: ISARIC WHO CCP-UK". 2. The acronym has been added. 3. The trial website has been changed from "" to "". 4. The participant information sheet has been added. 21/04/2020: Uploaded protocol (not peer reviewed) as an additional file. 27/03/2020: Trial’s existence confirmed by National Institute for Health Research (NIHR).